Al Ghannam joined Avalon Pharma in 2000 and has served as CEO since 2018, leading it into a publicly listed company in 2024. He oversees 19 countries in MEA. In 2025, the company entered into multiple licensing and tech transfer agreements with global pharma companies including Adalvo, Bio-Thera Solutions, and Dr. Reddy’s Laboratories to support localization, innovation and portfolio diversification. In H1 2026, it had $184 million in assets and recorded $71 million in revenues. Al Ghannam is also chairman and shareholder at Power Busbar, and board member at ANB Capital Alfayhaa fund.